BioNTech SE Stock Wiener Boerse

Equities

BNTX

US09075V1026

Biotechnology & Medical Research

End-of-day quote Wiener Boerse 06:00:00 2024-05-22 pm EDT 5-day change 1st Jan Change
93.1 EUR +0.92% Intraday chart for BioNTech SE +10.24% -2.49%
Sales 2024 * 2.8B 3.03B Sales 2025 * 2.77B 3B Capitalization 21.55B 23.38B
Net income 2024 * -435M -472M Net income 2025 * -508M -551M EV / Sales 2024 * 2.42 x
Net cash position 2024 * 14.78B 16.02B Net cash position 2025 * 13.76B 14.92B EV / Sales 2025 * 2.82 x
P/E ratio 2024 *
-49.5 x
P/E ratio 2025 *
-44.3 x
Employees 6,133
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.48%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.92%
1 week+10.24%
Current month+11.63%
1 month+12.71%
3 months+7.51%
6 months+1.97%
Current year-2.49%
More quotes
1 week
83.55
Extreme 83.55
95.30
1 month
81.05
Extreme 81.05
95.30
Current year
80.18
Extreme 80.18
103.00
1 year
80.18
Extreme 80.18
115.25
3 years
80.18
Extreme 80.18
394.10
5 years
65.89
Extreme 65.89
394.10
10 years
65.89
Extreme 65.89
394.10
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 08-06-01
Founder 57 08-06-01
Director of Finance/CFO 60 21-06-30
Members of the board TitleAgeSince
Director/Board Member 69 21-12-31
Director/Board Member 67 08-06-01
Chairman 53 08-06-01
More insiders
Date Price Change Volume
24-05-24 87.85 -5.64% 0
24-05-23 93.1 +0.92% 495
24-05-22 92.25 +9.56% 0
24-05-21 84.2 +0.42% 0
24-05-20 83.85 -0.71% 0

End-of-day quote Wiener Boerse, May 22, 2024

More quotes
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
89.32 EUR
Average target price
104.7 EUR
Spread / Average Target
+17.22%
Consensus